Avia Logo
Avia Logo
Avia Logo

Vendors /

nQ Medical, Inc.

nQ Medical, Inc.

nQ Medical, Inc.

badge_claimed
Claimed profile
nQ Medical is a digital therapeutics company addressing neurocognitive and neuromotor disorder via 24/7, passive data collection via personal devices. It is a frictionless, non-invasive, early detection, remote disease progression monitoring, and therapeutic measurement modality. nQ uses an artificial intelligence company to develop computational biomarkers that have been proven in five years of clinical trials to substantially change the way disease is managed for a wide range of neuromotor and neurocognitive disorders (Alzhemer's, Parkinson's, Multiple Sclerosis, ALS, concussion, et al. The platfomr focuses on analysis of user interaction with common electronic devices to capture functional decline related to neurodegenerative disorders. The fine control of typing and touch screen kinematics together with the frequent use of electronic devices allows for precise monitoring of small changes in neurodegeneration that frequently go unnoticed by clinicians. nQ allows for early detection of disease, 24/7, passive, at home, remote monitoring of disease progression and the measurement of impact of therapy at a fraction of the cost of current gold standards. There is no required task. Just use your device as your would normally use it. Of note, as one of the company's medical advisors, Zoltan Mari, MD, of the Cleveland Clinic, so aptly quoted: "As important as it is to fund novel compounds for treating diseases, it is also important to set the stage for maximum impact when those compounds are discovered and approved for use. It is impossible to find a cure without early detection. That's why drug candidates fail. When the FDA puts its stamp on the first disease modifying drugs, such early detection technologies will be instantly necessary." He goes on to state further: "We also need a disease progression marker. Nothing so far has managed to do very well (while being profoundly expensive). Much of our research and clinical interest is turning toward disease progression. All efforts should focus on readying and perfecting early detection tools and building effective, reliable, inexpensive ways of tracking disease and the impact of therapy over time.” nQ is that early detection, disease progression computational biomarker.
Read more

Filter products


Product Name

EMR compatibility

Star rating

Product attributes
  • Covid-19
  • Pediatric
  • In Epic App Orchard
  • In Cerner App Gallery

Keywords

Solutions

Filter products by clients


Used by

EMR used

Organization size

Type
  • AMC
  • Pediatric Facilities
  • ACO
  • Rural Presence

Products


Sort by:
Default
# of Clients- low to high
# of Clients- high to low
Alphabetical
Highest rated
products
Sort by:
Default
# of Clients- low to high
# of Clients- high to low
Alphabetical
Highest rated

Filter products


Product Name

EMR compatibility

Star rating

Product attributes
  • Covid-19
  • Pediatric
  • In Epic App Orchard
  • In Cerner App Gallery

Keywords

Solutions

Filter products by clients


Used by

EMR used

Organization size

Type
  • AMC
  • Pediatric Facilities
  • ACO
  • Rural Presence
Product Logo

Visit website

nQ is a computational biotechnology company with experience in digital phenotyping through AI-aided analysis of personal device interactions. We have developed digital biomarkers for Parkinson's disease in early and newly diagnosed/untreated stages of disease. In addition to PD, we are currently conducting a number of separate clinical trials to develop digital biomarkers individually relevant to Multiple Sclerosis, ALS, Alzheimer's disease, and mTBI with industry partners and academic centers including Cleveland Clinic and Massachusetts General Hospital. OUr AD trial has advanced to yield early and promising results measuring cognitive decline and delineating PD and AD symptomatology. In prodromal stages of neurodegenerative diseases such as PD, digital biomarkers offer possibility of detecting actual subclinical symptoms known to predict phenoconversion better than biochemical markers which often predict disease risk but not timing. Some key advantages of our digital biomarkers include: -Continuous, longitudinal, remote, real world quantification of psychomotor symptoms; -Patients are not burdened with completing structured tasks or clinic visits for data collection. Patients use their personal devices as they normally would and data is collected passively and transparently, often 24/7; -Patient privacy and security is ensured at each step of algorithm. Biomarkers perform even though content of what patients type on their personal devices kept confidential and secure. Specific to Parkinson's Disease: -Five peer reviewed publications reflecting 4 clinical trials demonstrating technical validation and clinical validation in PD patients; -Performance in correlating to UPDRS-III and differentiating healthy controls from from Parkinson's disease with AUC>0.90 in early PD patients thus far published. Follow-up work from our group and academic research by others have demonstrated continued increase in accuracy with increased data and refinement; -Performance in longitudinal symptom monitoring, distinguishing medication responders from non-responders. Use cases in multiple phases of clinical trial and in the clinic post-approval: Trial: -Cohort enrichment - pre-screening of patients to undergo more expensive or detailed diagnostic testing; -Symptom Fluctuation/Disease Progression Monitoring - characterize subpopulations of patient cohorts: responders, early progressors etc; -Outcome measure - Smartphone interaction is inherently relevant to daily function. Precise quantification can detect treatment responses missed by cruder metrics. Post-approval: -Disease screening for diagnostic referral; -Symptom monitoring as an independent or companion software to aid treatment titration, monitor compliance; -Generate real world data and evidence (RWE); -Supporting telehealth visits, access to patients in under-served/remote areas, via telemetry.
View full profile

Product Logo

Visit website

FDA Breakthrough Software as a Medical Device (SaMD) for early detection, remote monitoring of disease progression and measurement of the impact to therapy for at risk neurodegenerative patients. Psychomotor and cognition detection, monitoring, and therapeutic measurement. 

View full profile

Need help narrowing down products?

Add more criteria to see your match score for every vendor. It only takes a few minutes, just create a free account to get started.
ContactAVIA

About AVIA Connect

AVIA Connect is where innovative health systems and hospitals go to find the right digital health solutions. It’s built to efficiently search vendors and guide informed decisions, with tools like product comparisons, match scores, report generators, peer reviews, and market insights.

AVIA Connect is brought to you by AVIA, a trusted company and community of experts who guide health systems on their digital transformation journey.

Stay up to date

Keep up with the latest products and trends in digital health.